While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

Delays in diagnosing and treating psoriatic arthritis—a common inflammatory disorder affecting around 200,000 people in the U ...

Delays in diagnosing and treating psoriatic arthritis – a common inflammatory disorder affecting 112 in every 100,000 adults – are causing irreparable ...

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

A new study explores gaps in how patients and physicians view psoriatic arthritis (PsA) and recommends ways for clinicians to ...

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

Medically reviewed by Anita C. Chandrasekaran, MD Many people associate psoriatic arthritis (PsA) with itchy, scaly skin and ...

The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...

Affiliate content. Discover the best products for arthritis in hands, including supplements, creams, and tools designed to ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...